Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 1, 2015, Pages 57-71

  Joshi, N ^a,b   Kopec, A K ^b   O'Brien, K M ^a,b   Towery, K L ^b   Cline Fedewa, H ^b   Williams, K J ^b   Copple, B L ^a,b   Flick, M J ^c   Luyendyk, James P ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Blood coagulation; Fibrin; Fibrosis; Liver disease; Platelets

Indexed keywords

1 NAPHTHYL ISOTHIOCYANATE; ALPHA2BBETA3 INTEGRIN; ANTITHROMBOCYTIC AGENT; BILE ACID; DIGESTIVE TRACT AGENT; FIBGAMMADELTA5; FIBRINOGEN; INTEGRIN; MUTANT PROTEIN; PROTEINASE ACTIVATED RECEPTOR 4; SEROTONIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; FIBRINOGEN RECEPTOR; FIBRINOGEN VARIANT; PEPTIDE HYDROLASE; PROTEASE-ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BILE ACID BLOOD LEVEL; BILE DUCT INJURY; BILIARY TRACT FIBROSIS; CELL ACTIVATION; CHOLESTATIC HEPATITIS; CONTROLLED STUDY; EXPERIMENTAL LIVER FIBROSIS; EXPERIMENTAL LIVER INJURY; FIBRIN DEPOSITION; FIBROBLAST; LIVER CELL DAMAGE; LIVER NECROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SEROTONIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; WILD TYPE; ANIMAL; BLOOD; BLOOD CLOTTING; C57BL MOUSE; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; CHOLESTASIS; DEFICIENCY; GENETICS; GENOTYPE; KNOCKOUT MOUSE; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; MUTATION; NECROSIS; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; THROMBOCYTE;

1-NAPHTHYLISOTHIOCYANATE; ANIMALS; ANTITHROMBIN III; BILE ACIDS AND SALTS; BLOOD COAGULATION; BLOOD PLATELETS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHOLESTASIS; FIBRINOGENS, ABNORMAL; GENOTYPE; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; NECROSIS; PEPTIDE HYDROLASES; PHENOTYPE; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, THROMBIN; SEROTONIN; SIGNAL TRANSDUCTION;

EID: 84921051442     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12770     Document Type: Article

References (44)

1. Pihusch R, Rank A, Gohring P, Pihusch M, Hiller E, Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002; 37: 548-55.
2. Sullivan BP, Weinreb PH, Violette SM, Luyendyk JP. The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol 2010; 177: 2837-49.
3. Ben-Ari Z, Panagou M, Patch D, Bates S, Osman E, Pasi J, Burroughs A. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997; 26: 554-9.
4. Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni M, Caliendo G, Santagada V, Morelli A, Cirino G. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 2004; 39: 365-75.
5. Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol 2011; 35: 526-33.
6. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9: 1713-23.
7. Rullier A, Gillibert-Duplantier J, Costet P, Cubel G, Haurie V, Petibois C, Taras D, Dugot-Senant N, Deleris G, Bioulac-Sage P, Rosenbaum J. Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008; 294: G226-35.
8. Kallis YN, Scotton CJ, Mackinnon AC, Goldin RD, Wright NA, Iredale JP, Chambers RC, Forbes SJ. Proteinase activated receptor 1 mediated fibrosis in a mouse model of liver injury: a role for bone marrow derived macrophages. PLoS ONE 2014; 9: e86241.
9. Gaca MD, Zhou X, Benyon RC. Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol 2002; 36: 362-9.
10. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-9.
11. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-4.
12. Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004; 2: 1429-35.
13. Gear AR, Burke D. Thrombin-induced secretion of serotonin from platelets can occur in seconds. Blood 1982; 60: 1231-4.
14. Bennett JS, Berger BW, Billings PC. The structure and function of platelet integrins. J Thromb Haemost 2009; 7(Suppl. 1): 200-5.
15. Holmback K, Danton MJ, Suh TT, Daugherty CC, Degen JL. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. EMBO J 1996; 15: 5760-71.
16. Lisman T, Porte RJ. The role of platelets in liver inflammation and regeneration. Semin Thromb Hemost 2010; 36: 170-4.
17. Kodama T, Takehara T, Hikita H, Shimizu S, Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, Tadokoro S, Ido A, Tsubouchi H, Hayashi N. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 2010; 138: 2487-98, 98 e1-7.
18. Yoshida S, Ikenaga N, Liu SB, Peng ZW, Chung J, Sverdlov DY, Miyamoto M, Kim YO, Ogawa S, Arch RH, Schuppan D, Popov Y. Extra-hepatic PDGFB, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology 2014; 147: 1378-92.
19. Laschke MW, Dold S, Menger MD, Jeppsson B, Thorlacius H. Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile duct ligation-induced cholestasis. Br J Pharmacol 2008; 153: 148-56.
20. Sullivan BP, Wang R, Tawfik O, Luyendyk JP. Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies. Toxicol Sci 2010; 115: 286-94.
21. Bailie MB, Pearson JM, Lappin PB, Killam AL, Roth RA. Platelets and alpha-naphthylisothiocyanate-induced liver injury. Toxicol Appl Pharmacol 1994; 129: 207-13.
22. Jang JH, Rickenbacher A, Humar B, Weber A, Raptis DA, Lehmann K, Stieger B, Moritz W, Soll C, Georgiev P, Fischer D, Laczko E, Graf R, Clavien PA. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation. Hepatology 2012; 56: 209-18.
23. Lisman T, Weeterings C, de Groot PG. Platelet aggregation: involvement of thrombin and fibrin(ogen). Front Biosci 2005; 10: 2504-17.
24. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-8.
25. Kassel KM, Sullivan BP, Cui W, Copple BL, Luyendyk JP. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. Am J Pathol 2012; 181: 1287-95.
26. Luyendyk JP, Kassel KM, Allen K, Guo GL, Li G, Cantor GH, Copple BL. Fibrinogen deficiency increases liver injury and early growth response-1 (Egr-1) expression in a model of chronic xenobiotic-induced cholestasis. Am J Pathol 2011; 178: 1117-25.
27. Vandesompele J, De Preter K, Pattyn F, Poppe B, vanRoy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
28. Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, Birner P, Fleischmann E, Gruenberger B, Brostjan C, Gruenberger T. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology 2014; 60: 257-66.
29. Donahower B, McCullough SS, Kurten R, Lamps LW, Simpson P, Hinson JA, James LP. Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity. Am J Physiol Gastrointest Liver Physiol 2006; 291: G102-9.
30. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176: 1305-10.
31. Sullivan BP, Kopec AK, Joshi N, Cline H, Brown JA, Bishop SC, Kassel KM, Rockwell C, Mackman N, Luyendyk JP. Hepatocyte tissue factor activates the coagulation cascade in mice. Blood 2013; 121: 1868-74.
32. Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, Ellis E, Lakey AF, Burt AD, Douglass A, Wright MC, White SA, Jaffre F, Maroteaux L, Mann DA. Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease. Nat Med 2011; 17: 1668-73.
33. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA. Platelet-derived serotonin mediates liver regeneration. Science 2006; 312: 104-7.
34. Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, Cervantes-Barragan L, Ludewig B, Calzascia T, Bolinger B, Merkler D, Odermatt B, Bader M, Graf R, Clavien PA, Hegazy AN, Lohning M, Harris NL, Ohashi PS, Hengartner H, et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 2008; 14: 756-61.
35. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien PA. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 2007; 133: 608-18.
36. Luyendyk JP, Mackman N, Sullivan BP. Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. Toxicol Sci 2011; 119: 233-43.
37. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
38. Bledzka K, Smyth SS, Plow EF. Integrin alphaIIbbeta3: from discovery to efficacious therapeutic target. Circ Res 2013; 112: 1189-200.
39. Tronik-Le RD, Roullot V, Poujol C, Kortulewski T, Nurden P, Marguerie G. Thrombasthenic mice generated by replacement of the integrin alpha(IIb) gene: demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood 2000; 96: 1399-408.
40. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999; 103: 229-38.
41. Lieu HT, Batteux F, Simon MT, Cortes A, Nicco C, Zavala F, Pauloin A, Tralhao JG, Soubrane O, Weill B, Brechot C, Christa L. HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice. Hepatology 2005; 42: 618-26.
42. Gawaz M, Vogel S. Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. Blood 2013; 122: 2550-4.
43. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932-9.
44. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253. e1-4.